Clinical trialNCT05668962RecruitingPhase 2Interventional

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

SponsorMassachusetts General HospitalEnrollment30Follicular Thyroid CancerMetastatic Thyroid CancerPapillary Thyroid CancerThyroid CancerThyroid CarcinomaUnresectable Thyroid Gland Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Lori J. Wirth, MD
Massachusetts General Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Medstar Washington Hospital Center
Washington D.C., District of Columbia, United States
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
Recruiting
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Selpercatinib →Sodium Iodine I-131Thyrotropin alfa

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Mar 2023
Primary completion: 1 Mar 2025
Completion: 1 Jan 2026
Last update posted: 12 Dec 2024
Registered enrollment: 30
Registry id: NCT05668962

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.